Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396812 | 0.85 | HDAC6 (0.42) | HDAC6POLBKMT2ATDP1CASP6 | |
| SCHEMBL1608962 | 0.80 | HDAC6 (0.77) | HDAC6POLBKMT2ATDP1CASP6 | |
| SCHEMBL563497 | 0.79 | F2 (0.50) | HDAC6TDP1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL23201219 | 0.78 | F2 (0.49) | HDAC6TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL5770245 | 0.76 | HDAC6 (0.49) | HDAC6POLBKMT2ATDP1CASP6 | |
| SCHEMBL14723284 | 0.75 | HDAC6 (0.44) | HDAC6POLBKMT2ATDP1KDM4E | |
| SCHEMBL5947 | 0.74 | KDM4E (0.53) | HDAC6POLBKMT2ATDP1KDM4E | |
| SCHEMBL4402424 | 0.73 | CD40 (0.35) | HDAC6 | |
| SCHEMBL2353748 | 0.73 | DGAT1 (0.49) | HDAC6POLBKMT2ACASP6KDM4E | |
| Hydrochloric Acid SCHEMBL8689636 | 0.73 | HDAC6 (0.50) | HDAC6POLBKMT2ATDP1CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | claimed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2376484-B1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO SA (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8741923-B2 | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | MERCK SERONO SA (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2542549-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| WO-2011107530-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107530-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010069949-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2010-06-24 | — | — | WO | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | disclosed |
| CN-101321525-A | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | HDAC6 1079/4885POLB 3312/4885KMT2A 4379/4885 |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | HDAC6 218/4885POLB 2012/4885KMT2A 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.